Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Inclusion Criteria:

• Patients 18 years and older

• Diagnosed with normal tension glaucoma based on the following:

• IOP ≤ 21mmHg

• Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) lossconsistent with glaucoma

• Normal visual field OR visual field loss consistent with optic nerve or RNFLdefects within the last year

• Open angles assessed by gonioscopy

• Have been on latanoprost monotherapy for at least 6 weeks

Exclusion Criteria:

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

• Patients with angle closure glaucoma or secondary forms of glaucoma due toneovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucomadue to congenital anomalies.

• Other forms of secondary glaucoma.

• Patients with abnormal anterior segment examination other than cataract will beexcluded from the study.

• Patients who have had incisional surgery for glaucoma (eg: MIGs).

• Patients with refractory CME or CME persisting 3 months or more.

• Children, cognitive impaired and critically ill subjects will not be enrolled.

• Central Corneal Thickness (CCT) ≤ 500.

• Prior allergy to brimonidine or netarsudil, and known to have previously failedeither brimonidine or netarsudil.

• Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year priorto entering the study.

The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.